The company reported adjusted earnings of $7.7 billion, up 133% from a year earlier. Revenue soared to $24.1 billion, up 134%. Both easily cleared results forecast by analysts.
The vaccine business alone was responsible for more than 60% of the company’s sales, as vaccine revenue rose to $14.6 billion from only $1.7 billion a year earlier. The company said its COVID-19 vaccine sales accounted for $13 billion of that revenue. Revenue outside of its COVID-19 vaccine business was up a far more modest 7%.
This year, the COVID-19 vaccine has brought in revenue of $24.3 billion. And Pfizer said it expects a total of $36 billion from the vaccine for all of 2021 — nearly $12 billion more in revenue the final quarter of the year. And it said based on contracts it now has signed it expects revenue $29 billion from the COVID-19 vaccine in 2022. And that’s not necessarily all it will bring in.
“We continue to engage with governments regarding potential additional orders for 2022,” the company said. The company said it now expects full-year 2021 revenue of between $81 billion to $82 billion, up $2 billion from its earlier guidance.It also raised its earnings per share outlook by about 3% to 5% above what it had been expected to earn.